|
|
|
|
|
|
|
|
|
|
The mTORC½ inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737 | Molecular Cancer Therapeutics (abstract)
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.